Eminent Member of the Austrian Academy of Sciences, Professor Uwe B. Sleytr, Joins Avalon GloboCare's Scientific and Clinical Advisory Board
June 16, 2020 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that the...
Avalon GloboCare Announces Three-Way Material Transfer Agreement with Weill Cornell Medicine and Arbele Limited for Development of Next Generation Cellular Immunotherapy FLASH-CAR™ Technology
June 11, 2020 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has...
Avalon GloboCare Announces Diagnostic Platform for Point-of-Care Rapid Detection of COVID-19 (SARS-CoV-2) and Its Clinically Relevant Mutation Strains
June 08, 2020 09:00 ET
|
Avalon GloboCare Corp.
Entered Into Strategic Partnership with GensKey Medical Technology Co. Ltd. to Co-Develop and Commercialize Point-of-Care Antibody-Based IgG/IgM and PCR-Based SARS-CoV-2 Detection Systems, Both of...
Avalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR™ Technology for Blood Cancers
May 08, 2020 09:00 ET
|
Avalon GloboCare Corp.
RNA-Based Chimeric Antigen Receptor (CAR) Design Compatible with Broad Range of Immune Effector Cells, Including T (CAR-T) and Natural Killer Cells (CAR-NK) Without the Use of Viral VectorsCapable of...
Avalon GloboCare Partners with HydroPeptide, a Leader in Epigenetics Skin Care, to Accelerate Regenerative ACTEX™ Product Development and Commercialization
April 28, 2020 09:00 ET
|
Avalon GloboCare Corp.
Focused on Novel Combination of Clinical-Grade Exosomes and Hydropeptides for Cosmeceutical and Orthopedic Product DevelopmentSigned Three-Way Material Transfer Agreement between Avalon GloboCare,...
Avalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19 Lung Damage and Mortality
April 20, 2020 08:30 ET
|
Avalon GloboCare Corp.
Completed Functional Studies of Six QTY Code Designed Variant Cytokine Receptors as “Molecular Mop” to Remove Excessive Cytokines (“Cytokine Storm”) Related to Coronavirus Infection and Cellular...
Avalon GloboCare to Present at the 32nd Annual ROTH Conference on March 16, 2020
February 24, 2020 08:30 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it will...
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the “Cellular Therapy in the Asia Pacific Region” Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASTCT and CIBMTR Tandem Meeting 2020
February 04, 2020 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that its...
Avalon GloboCare to Present at Biotech Showcase™ 2020
January 06, 2020 08:30 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced its Chief...
Avalon GloboCare Partners with China (Nanjing) Cell Valley to Advance Cellular Medicines
December 20, 2019 08:30 ET
|
Avalon GloboCare Corp.
Forms Major Regional Hub in China for CellTech IndustryPartnership Delivers Synergy of Infrastructural Resources for Clinical Development and Bioprocessing Technologies in Cellular Therapy ...